XML 87 R76.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting - Disclosure of Operating Segment Information (Detail) - AUD ($)
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Revenue      
License revenue $ 0 $ 170,369 $ 0
Other income      
Research material sales 191,721 84,018 312,841
Grant income 3,314,001 4,459,974 3,549,965
Net gain on fair value movement of warrants 131,896 591,070 (8,663,013)
Net gain on foreign exchange 623,511 1,228,122 0
Interest income 938,999 224,520 105,327
Total revenue and other income 5,200,128 6,758,073 3,968,133
Segment Result (39,896,348) (32,210,792) (29,902,591)
Profit/(loss) before income tax expense (39,896,348) (32,210,792) (29,902,591)
Income tax expense 0 (34) [1] (33) [1]
Loss after income tax expense (39,896,348) (32,210,826) (29,902,624)
Total segment assets 147,448,990 102,169,550 82,030,533
Total segment liabilities 10,979,601 8,092,184 8,758,922
Immunotherapy [Member]      
Revenue      
License revenue   170,369  
Other income      
Research material sales 191,721 84,018 312,841
Grant income 3,314,001 4,459,974 3,549,965
Total revenue and other income 3,505,722 4,714,361 3,862,806
Segment Result (41,431,305) (33,929,768) (19,665,904)
Profit/(loss) before income tax expense (41,431,305) (33,929,768) (19,665,904)
Total segment assets 147,448,990 102,169,550 82,030,533
Total segment liabilities 10,979,601 8,092,184 8,758,922
Unallocated [member]      
Other income      
Net gain on fair value movement of warrants 131,896 591,070  
Net gain on foreign exchange 623,511 1,228,122  
Interest income 938,999 224,520 105,327
Total revenue and other income 1,694,406 2,043,712 105,327
Segment Result 1,534,957 1,718,976 (10,236,687)
Profit/(loss) before income tax expense $ 1,534,957 $ 1,718,976 $ (10,236,687)
[1] Income tax expense relates to tax payable for the Immutep subsidiary in the United States.